Risk Prediction of Dexmedetomidine-associated Hemodynamic Instability
Status:
Suspended
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Hypotension and bradycardia have been commonly associated with dexmedetomidine therapy,
occurring in 13% to 68% and 1% to 42% of patients, respectively. The variability in reported
incidence may be partially attributed to inconsistent definitions and study populations. The
significance of this hemodynamic instability is not only highlighted by its high incidence
but also the need for corrective interventions. In one study, hemodynamic instability
requiring clinical intervention occurred in nearly one third of ICU patients receiving
dexmedetomidine. Moreover, patients who experienced dexmedetomidine-associated hypotension
had a higher mortality rate than those who did not.